Table of Contents Table of Contents
Previous Page  130 / 164 Next Page
Information
Show Menu
Previous Page 130 / 164 Next Page
Page Background

130

ESTRO CONFERENCES

PRE-MEETING COURSES

FRIDAY 5 MAY 2017

Course directors:

T. Holch (UK) and C. Grau (DK)

COURSE AIM

To provide an overview of the current and potential

future roles of PROMs in radiotherapy research and

routine care settings.

LEARNINGOBJECTIVES

• To assess the role of PROMs in clinical practice and

within clinical trials.

• To evaluate the use of PROM-basedmodels to predict

patient risk of toxicity after radiotherapy and ion

beam therapy.

• To examine radiotherapy dose-volume relationships

involved in normal tissue complication probability

(NTCP).

WHO SHOULD ATTEND?

Clinicians, allied health care professionals and re-

searchers interested in:

• Improving their knowledge of the current and future

role of PROMs

• Improving patient outcomes in radiotherapy

• Developing models predicting risk of radiotherapy

toxicity.

CONTENT

Session 1: The PROMs value in cancer care:

• Improved doctor-patient communication

• Improved outcomes.

Session 2:What are themethodological and practical

challenges associated with the collection and use of

PROMs?

• Selection of measures, time points; electronic vs paper

• Translation into different languages

• Patient understanding

• Non-compliance.

Session 3: Implementation in radiotherapy research

and clinical practice in different cancers:

• REQUITE study (radiogenomics)

• Prostate lung cancer groups

• Head and neck

• Gynaecological.

Session 4: Correlating dose distribution and PROMs

Modelling NTCP relationship to CTCAE and why

PROs might be better validated evidence of change

from baseline

Session 5: Collection of electronic patient reported

outcomes (ePROMs)

• Feasibility of completion during and after treatment

• Early evaluation indicators

• Patient and staff acceptance

• Longitudinal follow up.

Session 6: Standard of PROM reporting in trials

PRO Consort guidelines applied to clinical trial re-

porting

Session 7: Future directions and research priorities

in the development of PROM measures and the ap-

plications of PROM data.

• Economics, relating PROMs to dose distribution

• Scalability of ePROM systems

• Cat vs traditional questionnaires.

Session 8: Discussion: How to integrate PROMs into

clinical practice

Practical ideas towards implementation.

CLINICAL PRE-MEETING COURSE

Patient Reported Outcome Measures (PROMs) in radiotherapy research and clinical

practice